Long-term management of acromegaly with sandostatin
Related Experiment Video
Updated: Oct 9, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
1Endocrine Division, Hippokrateion Hospital, Athens, Greece.
Abstract:
The present report illustrates the effectiveness of a long-acting somatostatin analog, SMS 201-995 (Sandostatin), in the chronic treatment of acromegaly. Daily doses of 50-300 micrograms were administered subcutaneously to 37 patients. Gradual dose increments induced a progressive GH decrease accompanied by a parallel reduction in plasma somatomedin C concentrations. There was a concomitant amelioration of clinical signs and symptoms throughout the investigational period. No escape phenomenon or tachyphylaxis was observed. It is concluded that chronic therapy with SMS 201-995 represents a promising medical alternative for the treatment of active acromegaly.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Mitral Stenosis III: Medical Management
Mitral Stenosis IV: Nursing Management
Cushing Syndrome I: Introduction

